Coremap Funding: How Much Did They Raise & Key Investors

How Much Did Coremap Raise?
Funding & Key Investors

Coremap has successfully secured a significant capital injection, bringing its cumulative financing to $69M. This latest round, characterized by a $35.5M strategic investment, underscores the company's robust growth trajectory within the specialized medical technology sector. By consistently attracting institutional backing, Coremap continues to solidify its position as a leader in the development of advanced diagnostic and therapeutic solutions for complex cardiac conditions.

The firm's ability to navigate multiple funding stages, from its initial Series A to this recent private equity infusion, highlights investor confidence in its proprietary technology. This capital will be instrumental in scaling operations and accelerating the clinical adoption of its atrial fibrillation management platforms.

What is Coremap?

Coremap

Manufacturing

Medical Devices & Equipment

Coremap operates at the intersection of biomedical engineering and clinical cardiology, focusing on the diagnosis and treatment of atrial fibrillation (AF). The company provides physicians with high-fidelity visualization tools designed to map irregular heartbeats with unprecedented precision. By addressing the underlying complexities of AF, Coremap aims to improve patient outcomes and streamline procedural workflows in electrophysiology labs. Their market position is defined by a commitment to rigorous research and a multidisciplinary approach, leveraging expertise from both medical and engineering domains to solve one of the most prevalent challenges in modern cardiovascular medicine.

How much funding has Coremap raised?

Coremap has raised a total of $69M across 3 funding rounds:

2020

Series A

$10.5M

2022

Series B

$23M

2026

Private Equity

$35.5M

Series A (2020): $10.5M with participation from Ronny Ginor and Qure Ventures

Series B (2022): $23M led by Russ Scully and Qure Ventures

Private Equity (2026): $35.5M, investors not publicly disclosed

Key Investors in Coremap

Qure Ventures

Qure Ventures is Israel's first exclusively focused digital health fund, investing in startups within the country's leading tech and digital health ecosystem.

Ronny Ginor

An individual investor providing strategic capital and industry expertise to support early-stage medical technology development.

Russ Scully

A private investor focused on backing high-growth healthcare innovations and medical device advancements.

What's next for Coremap?

With the recent influx of capital, Coremap is well-positioned to transition into a phase of rapid commercial expansion and clinical validation. The strategic focus will likely shift toward scaling manufacturing capabilities and expanding the reach of its diagnostic suite into global markets. Furthermore, the company is expected to leverage this financial runway to deepen its R&D pipeline, potentially exploring new therapeutic modalities that complement its existing AF visualization technology. As the company matures, the emphasis will remain on securing regulatory milestones and fostering strategic partnerships with major healthcare providers to ensure long-term market penetration and sustained clinical impact.

See full Coremap company page

See More Financial Insights